Biomarkers in Drug Discovery - Earlier Usage of Biomarkers in Optimization Stage to Reduce Drug Attrition Rate Significantly
- Published: October 2011
The analysts forecast the Global Imaging Biomarkers market to grow at a CAGR of 15.09 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing prevalence of cancer. The Global Imaging Biomarkers market has also been witnessing the emergence of personalized medicines. However, the poor regulatory and reimbursement systems could pose a challenge to the growth of this market.
The report, the Global Imaging Biomarkers Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market in the Americas, and the EMEA and APAC regions; it also covers the Global Imaging Biomarkers market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
The key vendors dominating this market space are Abbott Laboratories, Agilent Technologies Inc., Affymetrix Inc., Bio-Rad Laboratories Inc., F. Hoffmann La Roche Ltd., Gen-Probe Inc., and Siemens Healthcare.
Key questions answered in this report:
- What will the market size be in 2018 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report. SHOW LESS READ MORE >
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Geographical Segmentation
08. Buying Criteria
09. Market Growth Drivers
10. Drivers and their Impact
11. Market Challenges
12. Impact of Drivers and Challenges
13. Market Trends
14. Trends and their Impact
15. Vendor Landscape
15.1 Competitive Scenario
15.1.1 Key News
15.1.2 Mergers and Acquisitions
15.2 Key Vendors
15.3 Market Share Analysis 2013
16. Key Vendor Analysis
16.1 Abbott Laboratories
16.1.1 Business Overview
16.1.2 Business Segmentation
16.1.3 Key Information
16.1.4 SWOT Analysis
16.2 Affymetrix Inc.
16.2.1 Business Overview
16.2.2 Business Segmentation
16.2.3 Key Information
16.2.4 SWOT Analysis
16.3 Bio-Rad Laboratories Inc.
16.3.1 Business Overview
16.3.2 Business Segmentation
16.3.3 Key Information
16.3.4 SWOT Analysis
16.4 F. Hoffmann La Roche Ltd.
16.4.1 Business Overview
16.4.2 Business Segmentation
16.4.3 Key Information
16.4.4 SWOT Analysis
16.5 Siemens Healthcare
16.5.1 Business Overview
16.5.2 Key Information
16.5.3 SWOT Analysis
17. Other Reports in this Series
Exhibit 1: Market Research Methodology
Exhibit 2: Global Imaging Biomarkers Market 2013-2018 (US$ billion)
Exhibit 3: Global Imaging Biomarkers Market by Geographical Segmentation 2013
Exhibit 4: Business Segmentation of Abbott Laboratories
Exhibit 5: Business Segmentation of Affymetrix Inc.
Exhibit 6: Business Segmentation of Bio-Rad Laboratories Inc.
Exhibit 7: Business Segmentation of F. Hoffmann La Roche Ltd.
Commenting on the report, an analyst from the team said: “The Global Imaging Biomarkers market has been witnessing an increase in the number of strategic alliances being formed among organizations. Mergers and acquisitions help organizations grow rapidly, expand their business processes, and gain more market share. The introduction of innovative technologies by small and mid-sized companies is prompting major pharmaceutical and biotechnology companies to form strategic alliances with these smaller companies to identify various imaging biomarkers. The increase in strategic alliances is resulting in an increase in the application base for imaging biomarkers in drug discovery and diagnosis domains. For instance, in 2012, Genomic Health Inc. and OncoMed Pharmaceuticals announced a strategic alliance for Biomarker Research and Discovery using the Next-generation Sequencing process.”
According to the report, the use of imaging biomarkers in the field of drug discovery has increased considerably over the past few years. The increase in the demand for imaging biomarkers is primarily because of their ability to be used in target discovery and validation, identification of disease mechanisms, toxicity profiling, and proof-of-concept studies.
Further, the report states that one of the main challenges hindering the growth of this market is the presence of poor regulatory and reimbursements systems. The current regulatory and reimbursement systems present in various countries are not well-suited for imaging biomarker-based diagnostics. The development of novel and useful imaging biomarkers is also an expensive and time-consuming process.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
- Abbott Laboratories
- Agilent Technologies Inc.
- Affymetrix Inc.
- Bio-Rad Laboratories Inc.
- F. Hoffmann La Roche Ltd.
- Gen-Probe Inc.
- and Siemens Healthcare.